Clinical Trials Logo
  1. Home
  2. Mesotheliomas Pleural
  3. NCT04287829

Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients — PEMMELA  

Mesotheliomas Pleural Clinical Trial

Official title:
PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients(PEMMELA)

Clinical Trial Summary

There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%. Since the arrival of nivolumab plus ipilimumab as first line standard of care treatment in mesothelioma, no treatment options are investigated in this group of patients in the second line. So, there is a need for new treatment combinations with drugs that might exhibit a synergistic interaction with pembrolizumab.

Clinical Trial Description

There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%. So, there is a need for new treatment combinations with drugs that might exhibit a synergistic interaction with pembrolizumab. The mechanisms of actions of lenvatinib, which has a broad spectrum of activities, predicts many synergistic interactions with PD-1 blocking. The aim of this study is to characterize the potential clinical activity, toxicity and biomarkers of outcome of pembrolizumab - lenvatinib in patients with recurrent MPM. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04287829
Study type Interventional
Source The Netherlands Cancer Institute
Contact S Burgers, PhD
Phone 0031205129111
Email s.burgers@nki.nl
Status Recruiting
Phase Phase 2
Start date March 1, 2021
Completion date December 5, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05500508 - Oral AMXT 1501 Dicaprate in Combination With IV DFMO Phase 1/Phase 2
Recruiting NCT05304208 - dENdritic Cell Therapy Combined With SURgEry in Mesothelioma Phase 1
Recruiting NCT04400539 - The IMmunotherapy Pleural 5-ALA PDT Phase 2
Active, not recruiting NCT04300244 - Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma Phase 2
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Recruiting NCT05278975 - Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma Phase 1/Phase 2
Recruiting NCT04214015 - A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
Active, not recruiting NCT05451849 - A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2
Recruiting NCT03760575 - Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) Phase 1
Recruiting NCT04996017 - Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) Phase 3
Active, not recruiting NCT03054298 - CAR T Cells in Mesothelin Expressing Cancers Phase 1
Recruiting NCT06451536 - Ga-68 FAPI PET Before Immunotherapy N/A
Active, not recruiting NCT03907852 - Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer Phase 1/Phase 2